Proteins IL-22 , Mouse
- Known as:
- Proteins Interleukin-22 , Mouse
- Catalog number:
- C047
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-22 Mouse
Related genes to: Proteins IL-22 , Mouse
- Gene:
- IL22 NIH gene
- Name:
- interleukin 22
- Previous symbol:
- -
- Synonyms:
- ILTIF, IL-21, zcyto18, IL-TIF, IL-D110, TIFa, TIFIL-23, IL-22, MGC79382, MGC79384
- Chromosome:
- 12q15
- Locus Type:
- gene with protein product
- Date approved:
- 2001-03-12
- Date modifiied:
- 2019-04-23
- Gene:
- IL22RA1 NIH gene
- Name:
- interleukin 22 receptor subunit alpha 1
- Previous symbol:
- IL22R
- Synonyms:
- CRF2-9
- Chromosome:
- 1p36.11
- Locus Type:
- gene with protein product
- Date approved:
- 2000-10-16
- Date modifiied:
- 2015-12-11
Related products to: Proteins IL-22 , Mouse
Related articles to: Proteins IL-22 , Mouse
- Cytokines and cytokine receptors are important mediators in immunity and cancer development. Interleukin 22 (IL22) is one of the most important cytokines which has protumor effect. Given that common and specific roles of cytokines/receptors in multiple cancers, we conducted a pan-cancer study to investigate the role of IL22RA1 in cancer using The Cancer Genome Atlas (TCGA) database. Notably, we found IL22RA1 transcript was upregulated in 11 cancer types compared with their corresponding control. The mRNA expression level of IL22RA1 was highest in the pancreas among tumor tissues. The higher expression of IL22RA1 was associated with worse overall survival rate in patients. A total of 30 IL22RA1-correlated genes (e.g. , , , , , and ) are involved in the JAK/STAT pathway which promotes tumor progression. The upregulation of IL22RA1 in tumors was correlated with immune cell infiltration level. Higher expression of IL22RA2, IL20RB, IL10RA, IL10RB, TSLP, TYK2, STAT1 and STAT3 was associated with decreased overall survival rate in patients. IL22RA1 mutation was observed more in uterine cancer and melanoma compared with the other cancer types. Deactivation of IL22RA1 induced a lot of changes in gene expression. IL22RA1 mutants had upregulated DNA damage/repair genes in uterine cancer, whereas downregulated genes in the FoxO signaling pathway. In melanoma, mutation of IL22RA1 can upregulate the HIF signaling pathway but downregulate metabolic pathways. Our study suggests that IL22RA1/JAK/STAT signaling can be an important target for cancer treatment. - Source: PubMed
Publication date: 2022/07/08
Zhang ShuaiYang Guiyan